1160844-42-7

Basic information

• Product Name: Boc-Phe-Lys (alloc)-OH
• Synonyms: Boc-Phe-Lys (alloc)-OH
• CAS NO: 1160844-42-7
• Molecular Weight: 477.558
• Mol File: 1160844-42-7.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Boc-Phe-Lys (alloc)-OH(CAS DataBase Reference)
• NIST Chemistry Reference: Boc-Phe-Lys (alloc)-OH(1160844-42-7)
• EPA Substance Registry System: Boc-Phe-Lys (alloc)-OH(1160844-42-7)

Safety Data

• Hazardous Substances Data: 1160844-42-7(Hazardous Substances Data)

Upstream product

• 13734-34-4 N-tert-butoxycarbonyl-L-phenylalanine 
• 147529-99-5 N^Ε-allyloxycarbonyl-L-lysine hydrochloride 
• 3674-06-4 Boc-Phe-ONSu 
• 6298-03-9 (2S)-2-amino-6-{[(prop-2-en-1-yloxy)carbonyl]amino}hexanoic acid 
• 7535-56-0 N-t-butoxycarbonyl-L-phenylalanine 4-nitrophenyl ester 

Downstream Products

• 1160844-43-8 C₃₁H₄₂N₄O₇ 
• 1160844-44-9 C₃₈H₄₅N₅O₁₁ 
• 1197351-79-3 C₂HF₃O₂*C₅₀H₅₄N₈O₁₁ 

Relevant articles and documents

Synthesis, Characterization and in vitro Studies of a Cathepsin B-Cleavable Prodrug of the VEGFR Inhibitor Sunitinib

Since several decades, the prodrug concept has raised considerable interest in cancer research due to its potential to overcome common problems associated with chemotherapy. However, for small-molecule tyrosine kinase inhibitors, which also cause severe side effects, hardly any strategies to generate prodrugs for therapeutic improvement have been reported so far. Here, we present the synthesis and biological investigation of a cathepsin B-cleavable prodrug of the VEGFR inhibitor sunitinib. Cell viability assays and Western blot analyses revealed, that, in contrast to the non-cathepsin B-cleavable reference compound, the prodrug shows activity comparable to the original drug sunitinib in the highly cathepsin B-expressing cell lines Caki-1 and RU-MH. Moreover, a cathepsin B cleavage assay confirmed the desired enzymatic activation of the prodrug. Together, the obtained data show that the concept of cathepsin B-cleavable prodrugs can be transferred to the class of targeted therapeutics, allowing the development of optimized tyrosine kinase inhibitors for the treatment of cancer.

POLYMERIC SYSTEMS AND USES THEREOF IN THERANOSTIC APPLICATIONS

Polymeric systems useful for theranostic applications are disclosed. The polymeric systems comprise a fluorescent or fluorogenic moiety and a therapeutically active agent, each attached to the same or different polymeric moiety. The polymeric systems are designed such that a fluorescent signal is generated in response to a chemical event, preferably upon contacting an analyte (e.g., an enzyme) that is over- expressed in a diseased tissue or organ. Probes useful for inclusion in such polymeric systems, processes of preparing such probes and the polymeric systems, and uses thereof in diagnostic and/or theranostic applications are also disclosed.

Conjugates of a novel 7-substituted camptothecin with RGD-peptides as αvβ3 integrin ligands: An approach to tumor-targeted therapy

Eight conjugates of a novel camptothecin derivative (Namitecan, NMT) with RGD peptides have been synthesized and biologically evaluated. This study focused on factors that optimize the drug linkage to the transport vector. The different linkages investigated consist of heterofunctional glycol fragments and a lysosomally cleavable peptide. The linkage length and conformation were systematically modified with the purpose to understand their effect on receptor affinity, systemic stability, cytotoxicity, and solubility of the corresponding conjugates. Among the new conjugates prepared, C6 and C7 showed high receptor affinity and tumor cell adhesion, acceptable stability in murine blood, and high cytotoxic activity (IC50 = 8 nM). The rationale, synthetic strategy, and preliminary biological results will be presented.